Article

Transconjunctival sutureless vitrectomy evolves

With the instrumentation enhancements, it is easier for the surgeon to deal with peripheral pathology.

Bausch & Lomb has introduced a line of enhanced instruments for 25-gauge transconjunctival sutureless vitrectomy that addresses several critical issues, resulting in higher performance and a higher standard of care, according to Steven D. Schwartz, MD, chief of the retina division at the Jules Stein Eye Institute and associate professor of ophthalmology at UCLA's David Geffen School of Medicine, Los Angeles.

"I've used all of the 25-gauge systems, and this represents an evolutionary step within the Bausch & Lomb universe. This is a major advance," he said. "The trocars in the ESA system are much sharper, allowing for an even easier entry into the vitreous cavity. Also, studies have suggested that the ESA system has a very favorable wound-healing profile, and this new model maintains that potential advantage," he added.

"With instruments that are less malleable and hold their shape better, precision increases and 25-gauge procedures become safer for a broader range of patients. A set of higher-performance instruments allows one to deliver a higher standard or quality of care," Dr. Schwartz said.

"All those modifications represent substantial improvements to what is already an excellent system," Dr. Schwartz said.

Philip Ferrone, MD, a vitreoretinal specialist in Long Island and Queens, NY, who has conducted extensive research on wound healing with various 25-gauge entry systems, also noted the improvements in the alignment system. He explained that for the second-generation ESA, B&L changed the design of the cannula but kept the trocar portion the same. Thus the wound architecture, which was considered an advantage of the earlier instruments, was retained while the new design made it easier to load microsurgical instruments.

"What that led to was an easy-to-introduce cannula system with excellent healing of small wounds that are relatively atraumatic," Dr. Ferrone said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
© 2025 MJH Life Sciences

All rights reserved.